



# Truenat<sup>®</sup> HPV-HR Plus

Chip-based Real-Time Duplex PCR Test for  
High-Risk Human Papillomavirus Genotypes—  
16, 18, 31, 33, 35, 45, 52, and 58





# Cervical cancer is the fourth most common cancer among women worldwide.

To expand access, WHO's latest Target Product Profiles (TPPs) highlight the need for point-of-care nucleic acid tests (NATs) at the primary level and identify eight high-risk HPV genotypes—16, 18, 31, 33, 35, 45, 52, and 58—for targeted screening.\*

With over 85% of related deaths occurring in Sub-Saharan Africa, Southeast Asia, and parts of Latin America, the World Health Organization (WHO) in 2021, recommended HPV DNA testing as the primary screening method for age 25 and 30 onwards for women living with HIV and the general population respectively. \*

In line with these recommendations, Molbio has launched the Truenat HPV *HR* Plus assay, a gold-standard test covering the specified genotypes and enabling broader, decentralized cervical cancer screening.

## GLOBAL IMPACT

Cervical cancer represents around  
**4.5% of all newly diagnosed cancer cases worldwide.**

In 2022, HPV caused  
**6,60,000 cases**  
and around  
**3,50,000 deaths**  
globally.

Over 96% of cases of  
**cervical cancers**  
are linked to high-risk  
**HPV genotypes.**

# SCREENING AND DIAGNOSIS OF HPV WITH **Truenat**<sup>®</sup> HPV-HR Plus

Truenat is a WHO-endorsed, fully automated, battery-operated real-time PCR platform that supports screening and detection of over 40 diseases, including HPV, at the point-of-care.

The new assay - HPV-HR Plus, featuring two dedicated channels, can detect both the most aggressive HPV genotypes—16 and 18—as well as other high-risk types including 31, 33, 35, 45, 52, and 58, which together account for over 96% of cervical cancer cases worldwide (\*Clifford & Wei, 2024).

Robust and portable, Truenat is well-suited for widescale screening in diverse settings and provides results in under one hour, enabling fast, accurate detection and supporting early diagnosis of cervical cancer in women.



# KEY FEATURES



## User-friendly

Requires minimal human resource training



## Minimal extracted elute volume

Requires 6µL for high-efficiency



## Single-use disposable consumables



## Lyophilized, ready-to-use PCR reagents



## Smart chip

Replete with batch-specific data



## Minimal biosafety requirements

Can be used even in resource limited settings



## Reagent stability

Room temperature stable reagents



## Contamination/evaporation-resistant design

To provide maximum control

## ORDERING INFORMATION

| Pack Size | 5T        | 25T       | 50T       |
|-----------|-----------|-----------|-----------|
| Cat. No.  | 601840005 | 601840025 | 601840050 |

## Reference

<sup>1</sup> World Health Organization. (2021, July 6). New recommendations for screening and treatment to prevent cervical cancer.

<sup>2</sup> World Health Organization. (2024). Target product profiles for human papillomavirus screening tests to detect cervical pre-cancer and cancer.



**MOLBIO DIAGNOSTICS LIMITED**  
L-46, Phase II D, Verna Industrial Estate,  
Verna, Goa - 403722, India



+91 8326724888



sales@molbiodiagnostics.com



www.molbiodiagnostics.com



customersupport@molbiodiagnostics.com